https://scholars.lib.ntu.edu.tw/handle/123456789/557663
標題: | Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review | 作者: | Yang, Chih-Jen Wei, Yu-Jui Chang, Hsu-Liang Chang, Pi-Yu Tsai, Chung-Chen Chen, Yen-Hsu PO-REN HSUEH |
關鍵字: | Compassionate use; Coronavirus disease 2019; Remdesivir; Severe acute respiratory syndrome coronavirus 2 | 公開日期: | 二月-2021 | 卷: | 54 | 期: | 1 | 來源出版物: | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi | 摘要: | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/557663 | ISSN: | 16841182 | DOI: | 10.1016/j.jmii.2020.09.002 | SDG/關鍵字: | alanine aminotransferase; angiotensin receptor antagonist; azithromycin; chloroquine; colchicine; convalescent plasma; corticosteroid; dipeptidyl carboxypeptidase inhibitor; favipiravir; hemoglobin; hydroxychloroquine; ibuprofen; indometacin; interferon; lopinavir plus ritonavir; placebo; remdesivir; ribavirin; tocilizumab; adenosine phosphate; alanine; antivirus agent; remdesivir; acute respiratory failure; anemia; antiviral activity; artificial ventilation; constipation; coronavirus disease 2019; drug efficacy; drug mechanism; drug withdrawal; estimated glomerular filtration rate; evidence based medicine; headache; human; hyperbilirubinemia; hypertransaminasemia; hypoalbuminemia; hypokalemia; hypotension; kidney failure; loading drug dose; lower respiratory tract infection; maculopapular rash; multicenter study (topic); nausea; nonhuman; oxygen therapy; pandemic; phase 3 clinical trial (topic); preclinical study; randomized controlled trial (topic); Review; thrombocytopenia; virus pneumonia; China; clinical trial (topic); drug effect; drug therapy; epidemiology; pandemic; Adenosine Monophosphate; Alanine; Antiviral Agents; China; Clinical Trials as Topic; COVID-19; Humans; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。